Abstract: A composition useful in treating Multiple Sclerosis and HTLV-1 myelopathy in humans comprises:i) a peptide having as its active portion, an amino acid sequence of the formula:-Thr-Thr-Asn-Tyr-Thr-; andii) a pharmaceutically acceptable carrier for said peptide.
Type:
Grant
Filed:
November 8, 1995
Date of Patent:
November 11, 1997
Assignee:
Reed MacFadden, Ltd.
Inventors:
Douglas K. MacFadden, Peter L. Carlen, Penelope Reed Doob
Abstract: A biologically active peptide selected from growth factors, peptide hormones, interferons and cytokines and analogues and derivatives thereof, and bearing at least one chelating group linked to an amino group of said peptide, the chelating group being capable of complexing a detectable element and such amino group having no significant binding affinity to target receptors, are complexed with a detectable element and are useful as a pharmaceutical, e.g. a radiopharmaceutical for in vivo imaging of target tissues or for therapy.
Abstract: The present invention relates to the field of immunossays for metal ions. The invention presents: metal ion-ligand coordination complexes ("MLC"), novel ligands, antibodies specific for MLC, immunoassays utilizing the foregoing, and methods for selecting said antibodies.
Abstract: Peptides derived from proteins associated with bacterial adherence to mammary ductile epithelium are useful in vaccine preparation for preventing mastitis. Methods for determining Microbial adherence provide rational vaccine design.
Abstract: A method for generating multiple mimics of an active site of a molecule, such as a protein, using computer modeling of the active site. A putative active site is identified, and the amino acids, or residues, purportedly responsible for the biological activity in question are located. These are represented as virtual residues in a model of the active site. The method generates many different possible representations of the active site of the selected protein, presenting the user with a choice of premodeled molecules for synthesis and testing as a substitute for the protein.
Abstract: A recombinant plasmid comprises the cyaC and the cyaA genes of Bordetella which directs the expression of Bordetella, adenylate cyclase in a transformed host cell. A recombinant DNA molecule can comprise the Bordetella cyaA gene containing at least one insertion of a heterologous DNA sequence at at least one permissive site. In addition, a recombinant Bordetella adenylate cyclase comprises a heterologous epitope at a permissive site. Methods of inducing a specific B cell, helper T cell, and CTL cell immune response are provided.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
October 21, 1997
Assignee:
Institut Pasteur
Inventors:
Daniel Ladant, Claude Leclerc, Peter Sebo, Agnes Ullmann
Abstract: Peptide-chelator conjugates are provided that when labelled with a traceable metal are useful for diagnostic imaging of sites of inflammation. The peptide component is an antagonist of the naturally occurring tetrapeptide tuftsin while the chelator component serves as a labelling site for metals, in particular radionuclide metals such as technetium-99m.
Abstract: Compounds which Inhibit interleukin-1.beta. protease activity, pharmaceutical compositions containing the compounds and methods using the compounds are provided. The compounds have the formula ##STR1## wherein n is 0-2; each AA is Independently L-valine or L-alanine;R.sub.1 is selected from the group consisting of N-?4(N,N-dimethylaminomethyl)!benzoyl, N-benzoyloxycarbonyl, N-methyl-N-?4-(pyridyl)methyl!, N-?4-(pyddyl)methyl!carbonyl, N-3-(piperidinopropionyl), N-?4-(morpholinoethoxy)benzoyl, N-2-(quinuclidinyl)carbonyl, N-(3-pyridyl)methoxy carbonyl, N-(2-pyddyl)methoxy carbonyl, N-methyl-N-benzyl carbonyl, N-methyl-N-?2-(4-pyridyl)ethyl!carbonyl, and N-(N-phenylpiperazino) carbonyl; andR.sub.8, R.sub.9 and R.sub.10 are as defined below.
Type:
Grant
Filed:
October 16, 1996
Date of Patent:
October 14, 1997
Assignee:
Sanofi
Inventors:
Roland E. Dolle, Jasbir Singh, David A. Whipple, Catherine Prouty, Prasad V. Chaturvedula, Stanley J. Schmidt, Mohamed M. A. Awad, Denton W. Hoyer, Tina Morgan Ross
Abstract: A pharmaceutical preparation for the therapy of immune deficiency conditions comprising an active principle--a peptide of the structure: H-L-Glu-L-Trp-OH and a pharmaceutically acceptable vehicle.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
October 7, 1997
Assignee:
Cytoven J.V.
Inventors:
Vyacheslav G. Morozov, Vladimir K. Khavinson
Abstract: The invention provides materials and methods for synthesizing novel beta-turn mimetics, as well as the novel beta-turn mimetics themselves, and peptides containing the same. Also provided are novel synthetic nonpeptide therapeutic molecules designed upon the interactions between beta-turn mimetics or peptides containing the same, and receptors or enzymes.
Abstract: The invention provides materials and methods for synthesizing novel reverse turn mimetics, as well as peptides containing the same. Also provided are novel synthetic nonpeptide therapeutic molecules designed upon the interactions between reverse turn mimetics or peptides containing the same, and receptors, antibodies, or enzymes.
Abstract: The invention provides materials and methods for synthesizing novel reverse turn mimetics, as well as peptides containing the same. Also provided are novel synthetic nonpeptide therapeutic molecules designed upon the interactions between reverse turn mimetics or peptides containing the same, and receptors, antibodies, or enzymes.
Abstract: The complete amino acid and nucleotide sequence for adenylate cyclase stimulating factor is provided, thereby facilitating the synthesis of ACSF in recombinant cell culture. ACSF amino acid sequence variants and ACSF antibodies are provided which are useful in the treatment of humoral hypercalcemia of malignancy or in immunoassays for ACSF. In particular, antibodies capable of binding only the C-terminal domains of ACSF are useful in immunoassays for ACSF which avoid interference by parathyroid hormone. Also provided are novel polypeptides selected from the group of the ACSF basic peptide, the ACSF C-terminal peptide, or the ACSF domain containing both of the basic and C-terminal peptides.
Type:
Grant
Filed:
January 4, 1994
Date of Patent:
September 16, 1997
Assignees:
The University Of Melbourne, Genentech, Inc.
Abstract: Mammalian expression systems for the production of HCV proteins. Such expression systems provide high yields of HCV proteins, and enable the development of diagnostic and therapeutic reagents which contain glycosylated structural antigens and also allow for the isolation of the HCV etiological agent.
Type:
Grant
Filed:
May 30, 1995
Date of Patent:
September 16, 1997
Assignee:
Abbott Laboratories
Inventors:
James M. Casey, Suzanne L. Bode, Billy J. Zeck, Julie Yamaguchi, Donald E. Frail, Suresh M. Desai, Sushil G. Devare
Abstract: Oil based vaccines often cause serious local side effects at the site of administration and/or have a high viscosity which make said vaccines difficult to handle. Vaccines comprising as an adjuvant a stable emulsion of tocols in water do not display these undesired effects and induce good immune responses.
Abstract: Glucagon analogs characterized principally by substitution of amino acid residues at positions 9, 11, 16, and 21 with or without a histidine residue at the amino terminus are useful adjuncts to insulin therapy.
Abstract: This application discloses seven newly synthesized pentapeptide amides and our tetrapeptide amides. The synthesis utilized both naturally occurring and modified amino acids; the modified amino acids are constituents of the well known dolastatin 10 and dolastatin 15 which are structurally distinct peptides with excellent antineoplastic activity. These peptides were constructed by introducing a peptide bond between selected amino acids and modified amino acids and coupling the resulting di- and tri-peptides to obtain peptides having a high anticancer activity against a series of human cancer cell lines.
Type:
Grant
Filed:
June 13, 1996
Date of Patent:
September 9, 1997
Assignee:
Arizona Board of Regents acting on behalf of Arizona State University
Inventors:
George R. Pettit, Jayaram K. Srirangam, Michael D. Williams
Abstract: A therapeutic preparation for inhalation which comprises insulin and a substance which enhances the absorption of insulin in the lower respiratory tract, is provided in the form of a powder preparation suitable for inhalation.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
August 19, 1997
Assignee:
AB Astra
Inventors:
Kjell Goran Erik Backstrom, Carl Magnus Olof Dahlback, Peter Edman, Ann Charlotte Birgit Johansson
Abstract: The present invention provides peptides and compounds which inhibit the enzyme activity of Type II phospholipases A.sub.2. The preferred compounds are pentapeptides. Where the phospholipase is human Type II phospholipase A.sub.2 the preferred peptides are FLSYK and KFLSY.
Type:
Grant
Filed:
March 3, 1994
Date of Patent:
August 12, 1997
Assignee:
Garvan Institute of Medical Research
Inventors:
Albert Peng Sheng Tseng, Adam Inglis, Kieran Scott